Vir Biotechnology 거래 VIR

매도
 매수

VirBiotechnology 실시간 차트

5m 15m 30m 1h 4h 1d 1w

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

VirBiotechnology news

최신 뉴스

더 보기
Ghko B 2025 Jun 05, 16:00

Trump-Musk Relationship Collapses: Tesla Stock Drops 10%

Stocks
Ghko B 2025 Jun 05, 16:00

What are the most active stocks: RKLB, LULU, WBA, LMT, SQQQ

Stocks
Darius Anucauskas 2025 Jun 05, 16:00

Morning Note: NFP Weakness Could Pressure USD While Gold Continues to Climb

Morning Note Gold Fed Forex USD
Tommy Yap 2025 Jun 05, 16:00

Morning Note: U.S. Payroll Growth, Canada Job Market Weakens, Tesla Risks EV Credits

Morning Note Fed Forex CAD TSLA
Ghko B 2025 Jun 04, 16:00

SOFI Stock Analysis: What is the 5-year forecast for SoFi?

Stocks
Ghko B 2025 Jun 04, 16:00

VOO Performance Analysis: Is Vanguard S&P 500 ETF good to invest in?

ETFs
Ghko B 2025 Jun 04, 16:00

Intel Stock Is Trending Now: What to Know about Intel Corporation (INTC)?

Stocks
Tommy Yap 2025 Jun 04, 16:00

Morning Note: ECB Rate Cut Expected; Canada PMI in Focus; EUR/USD, USD/CAD

Morning Note Forex CAD

정보

스프레드

0.05

스프레드(%)

0.9276 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 개장

금요일

13:31 - 19:59

월요일

13:31-19:59

화요일

13:31-19:59

수요일

13:31-19:59

목요일

13:31-19:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

729188544

발행 주식 수

138238000

수익 날짜 (다음)

0000-00-00

배당수익률

배당락일

예상 연간 배당금

0

예상 연간 배당수익률

0

EPS

-4.13

이 상품에 대해 자세히 알아보기

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

관련 상품

자산
매도
매수
변동(%)

지금 거래하기

지금 거래하기

지금 거래하기

지금 거래하기
view_all_instruments

latest_education_articles

더 보기
Trustpilot